A prospective, open-label, single-arm, investigator-initiated clinical trial to assess the efficacy, safety and durability of faricimab in patients with inadequate response to current treatment for neovascular age-related macular degeneration: protocol design and rationale for the FURGGHORN Study.
- DOI
- 10.1136/bmjophth-2025-002326
- Published
- 2025 Oct 20
- Container
- BMJ open ophthalmology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/bmjophth-2025-002326,
title = {A prospective, open-label, single-arm, investigator-initiated clinical trial to assess the efficacy, safety and durability of faricimab in patients with inadequate response to current treatment for neovascular age-related macular degeneration: protocol design and rationale for the FURGGHORN Study.},
author = {Phan LT and Hong T and Chang JH and Mehta H and Fraser-Bell S and Cheung GCM and Broadhead GK and Chang AA},
year = {2025},
journal = {BMJ open ophthalmology},
doi = {10.1136/bmjophth-2025-002326},
url = {https://doi.org/10.1136/bmjophth-2025-002326}
}RIS
TY - JOUR TI - A prospective, open-label, single-arm, investigator-initiated clinical trial to assess the efficacy, safety and durability of faricimab in patients with inadequate response to current treatment for neovascular age-related macular degeneration: protocol design and rationale for the FURGGHORN Study. AU - Phan LT AU - Hong T AU - Chang JH AU - Mehta H AU - Fraser-Bell S AU - Cheung GCM AU - Broadhead GK AU - Chang AA PY - 2025 JO - BMJ open ophthalmology DO - 10.1136/bmjophth-2025-002326 UR - https://doi.org/10.1136/bmjophth-2025-002326 ER -
APA
LT, P., T, H., JH, C., H, M., S, F., GCM, C., GK, B., & AA, C. (2025). A prospective, open-label, single-arm, investigator-initiated clinical trial to assess the efficacy, safety and durability of faricimab in patients with inadequate response to current treatment for neovascular age-related macular degeneration: protocol design and rationale for the FURGGHORN Study.. BMJ open ophthalmology. https://doi.org/10.1136/bmjophth-2025-002326
Source records
- pubmed · retrieved 2026-09-26T12:36:28.567Z
- europe-pmc · retrieved 2026-09-26T12:36:28.558Z
- doaj · retrieved 2026-09-26T12:36:28.544Z